University College Dublin School of Medicine, UCD Catherine McAuley Education & Research Centre, Dublin, Ireland.
Clin Pharmacol Ther. 2018 Mar;103(3):396-398. doi: 10.1002/cpt.999.
There is an expanding body of literature regarding the utility of novel biomarkers in drug-induced kidney injury (DIKI) and other forms of acute kidney injury (AKI). The authors could not thoroughly review this topic without referring to and acknowledging this work. Included is a list of additional articles (see Supplementary Reading List) that have been referenced, but not cited within the body of the text. These references have provided data used within this article and have allowed the authors to discuss the epidemiology of DIKI, its classification, the utility of specific biomarkers, and the impact that comorbid illness and medications can have on their levels.
关于新型生物标志物在药物性肾损伤（DIKI）和其他类型急性肾损伤（AKI）中的应用，有越来越多的文献对此进行了探讨。如果不参考和承认这些工作，作者就无法全面地综述这个主题。此外，还列出了一些参考文献（见补充阅读清单），这些参考文献虽然没有在正文中引用，但也被提及了。这些参考文献提供了本文使用的数据，并使作者能够讨论 DIKI 的流行病学、分类、特定生物标志物的应用，以及合并症和药物对其水平的影响。
